Literature DB >> 10885618

In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines.

M J Grilló1, N Bosseray, J M Blasco.   

Abstract

Four seed lots and fourteen batches of Brucella melitensis Rev 1 and B. abortus B19 living anti-Brucella commercial vaccines obtained from six Spanish laboratories were tested in vitro and in vivo in the reference mouse model for quality control. All the strains tested showed the characteristic morphology of their respective Rev 1 or B19 reference strains with the exception of three Rev 1 strains: seed lot SL2 and commercial vaccine R3, in which giant colonies were predominant, and commercial vaccine R5, in which 5% rough colonies were detected. Strains SL2 and R5 (but not the R3) had a deficient activity when tested in the mouse model. All strains but two (Rev 1 strain R1 and B19 strain B2) had standard resistance/ sensitivity patterns to streptomycin and penicillin G. Strains R1 and B2 had an increased resistance to penicillin when incubated in a 10% CO2 atmosphere and both strains showed an increased residual virulence in mice. As residual virulence and immunogenicity in mice were not always correlated one another nor with the in vitro tests, all tests should be performed to control properly the anti-Brucella live vaccines. A computerized statistical procedure to calculate the residual virulence of vaccines is proposed as an alternative to that used in the current method.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10885618     DOI: 10.1006/biol.2000.0249

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  14 in total

Review 1.  Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions.

Authors:  Paul de Figueiredo; Thomas A Ficht; Allison Rice-Ficht; Carlos A Rossetti; L Garry Adams
Journal:  Am J Pathol       Date:  2015-04-17       Impact factor: 4.307

2.  Protection Provided by an Encapsulated Live Attenuated ΔabcBA Strain of Brucella ovis against Experimental Challenge in a Murine Model.

Authors:  Ana Patrícia C Silva; Auricélio A Macêdo; Teane M A Silva; Luana C A Ximenes; Humberto M Brandão; Tatiane A Paixão; Renato L Santos
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

3.  Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model.

Authors:  D Monreal; M J Grilló; D González; C M Marín; M J De Miguel; I López-Goñi; J M Blasco; A Cloeckaert; I Moriyón
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 4.  Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans.

Authors:  Jinkyung Ko; Gary A Splitter
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

5.  Bioluminescence Imaging of Colonization and Clearance Dynamics of Brucella Suis Vaccine Strain S2 in Mice and Guinea Pigs.

Authors:  Xiwen Wang; Zhiping Li; Bo Li; Hang Chi; Jiakuan Li; Hongchao Fan; Ruizhi Yao; Qianxue Li; Xiaolin Dong; Man Chen; Han Qu; Yuanyuan Wang; Weicun Gao; Yutian Wang; Yu Sun; Rui Sun; Jun Qian; Zhiping Xia
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

6.  Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein.

Authors:  Apurba K Bhattacharjee; Lillian Van de Verg; Mina J Izadjoo; Liang Yuan; Ted L Hadfield; Wendell D Zollinger; David L Hoover
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

Review 7.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

8.  Encapsulated Brucella ovis Lacking a Putative ATP-Binding Cassette Transporter (ΔabcBA) Protects against Wild Type Brucella ovis in Rams.

Authors:  Ana Patrícia C Silva; Auricélio A Macêdo; Luciana F Costa; Cláudia E Rocha; Luize N N Garcia; Jade R D Farias; Priscilla P R Gomes; Gustavo C Teixeira; Kessler W J Fonseca; Andréa R F Maia; Gabriela G Neves; Everton L Romão; Teane M A Silva; Juliana P S Mol; Renata M Oliveira; Márcio S S Araújo; Ernane F Nascimento; Olindo A Martins-Filho; Humberto M Brandão; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

9.  Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export.

Authors:  David González; María-Jesús Grilló; María-Jesús De Miguel; Tara Ali; Vilma Arce-Gorvel; Rose-May Delrue; Raquel Conde-Alvarez; Pilar Muñoz; Ignacio López-Goñi; Maite Iriarte; Clara-M Marín; Andrej Weintraub; Göran Widmalm; Michel Zygmunt; Jean-Jacques Letesson; Jean-Pierre Gorvel; José-María Blasco; Ignacio Moriyón
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

10.  Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection.

Authors:  Pilar Sancho; Carmen Tejedor; Rebeca S Sidhu-Muñoz; Luis Fernández-Lago; Nieves Vizcaíno
Journal:  Vet Res       Date:  2014-06-04       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.